scholarly journals Long leukocyte telomere length in prostate cancer patients at diagnosis is associated with poor metastasis-free and cancer-specific survival

Tumor Biology ◽  
2017 ◽  
Vol 39 (2) ◽  
pp. 101042831769223 ◽  
Author(s):  
Ulrika Svenson ◽  
Göran Roos ◽  
Pernilla Wikström
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Telomere Length ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Risk Groups ◽  
Leukocyte Telomere Length ◽  
Cancer Specific Survival ◽  
Control Subjects ◽  
Relative Telomere Length

Previous studies have suggested that leukocyte telomere length is associated with risk of developing prostate cancer. Investigations of leukocyte telomere length as a prognostic factor in prostate cancer are, however, lacking. In this study, leukocyte telomere length was investigated both as a risk marker, comparing control subjects and patient risk groups (based on serum levels of prostate-specific antigen, tumor differentiation, and tumor stage), and as a prognostic marker for metastasis-free and cancer-specific survival. Relative telomere length was measured by a well-established quantitative polymerase chain reaction method in 415 consecutively sampled individuals. Statistical evaluation included 162 control subjects without cancer development during follow-up and 110 untreated patients with newly diagnosed localized prostate cancer at the time of blood draw. Leukocyte telomere length did not differ significantly between control subjects and patients, or between patient risk groups. Interestingly, however, and in line with our previous results in breast and kidney cancer patients, relative telomere length at diagnosis was an independent prognostic factor. Patients with long leukocyte telomeres (⩾median) had a significantly worse prostate cancer–specific and metastasis-free survival compared to patients with short telomere length. In contrast, for patients who died of other causes than prostate cancer, long relative telomere length was not coupled to shorter survival time. To our knowledge, these results are novel and give further strength to our hypothesis that leukocyte telomere length might be used as a prognostic marker in malignancy.

scholarly journals The association between relative leukocyte telomere length of prostate cancer patients at diagnosis with cancer prognostic parameters

2021 ◽  
Vol 42 (1) ◽  
pp. 27-33
Author(s):  
Thiraphat Saengmearnuparp ◽  
◽  
Bannakij Lojanapiwat ◽  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Telomere Length ◽  
Prognostic Marker ◽  
Quantitative Polymerase Chain Reaction ◽  
Leukocyte Telomere Length ◽  
Current Recommendation ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Pertinent Data

Objectives: In this study, relative leukocyte telomere length (LTL) was investigated as a prognostic marker to evaluate association of LTL at the time of diagnosis and prostate cancer-specific survival, metastasis-free survival, overall survival, with castrate-resistant prostate cancer (CRPC). Materials and Methods: In this retrospective cohort study, pertinent data from 81 patients were collected. Patients underwent prostate cancer (PCa) treatment procedures determined by staging and current recommendation. Blood samples from suspected PCa patients were obtained before the initiation of diagnosis and treatment. LTL was determined by the quantitative polymerase chain reaction method. Relative LTL was compared to the main clinical outcome measures. Prostate cancer-specific survival, metastasis-free survival, overall survival and CRPC were calculated retrospectively, for a mean follow-up period of 30 months. Results: This analysis showed relative LTL was not associated with tumor stage, Gleason score, grade group, metabolic disease, or smoking. However, older age was significantly associated with short LTL (p < 0.001). All main outcomes were not associated with LTL. In contrast, a subgroup analysis of patients who underwent primary androgen deprivation therapy (ADT) showed a CRPC association with relatively long LTL (p = 0.039). To our knowledge, these results are novel and give further strength to our hypothesis that relative LTL might be used as a prognostic marker in PCa especially in patients who will receive primary ADT. Conclusion: Aging was significantly associated with relatively short LTL. There was no significant association between LTL in PCa patients at diagnosis and cancer-specific survival, metastasis-free survival, or overall survival. However, patients who underwent ADT treatment alone showed CRPC associated with relatively long LTL.

Relative telomere length is associated with mortality in prostate cancer patients

2019 ◽  
Vol 18 (11) ◽  
pp. e3488
Author(s):  
T. Langsenlehner ◽  
K. Lukasiak ◽  
H-J. Gruber ◽  
M. Hermann ◽  
U. Langsenlehner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Telomere Length ◽  
Cancer Patients ◽  
Relative Telomere Length

scholarly journals Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients

EBioMedicine ◽  
2020 ◽  
Vol 52 ◽  
pp. 102616 ◽  
Author(s):  
Junfeng Xu ◽  
Wen-Shin Chang ◽  
Chia-Wen Tsai ◽  
Da-Tian Bau ◽  
Yifan Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Telomere Length ◽  
Cancer Patients ◽  
Localized Prostate Cancer ◽  
Leukocyte Telomere Length ◽  
Aggressive Prostate Cancer

Effect of androgen deprivation therapy on intraductal carcinoma of the prostate (IDC-P), a prognostic factor for prostate cancer.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 146-146
Author(s):  
Masashi Kato
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Needle Biopsy ◽  
Androgen Deprivation ◽  
Intraductal Carcinoma ◽  
Cancer Specific Survival ◽  
Carcinoma Of The Prostate

146 Background: The presence of intraductal carcinoma of the prostate (IDC-P) is reported to be an adverse prognostic factor for cancer-specific survival (CSS) in localized and metastatic prostate cancer patients. However, there is no data indicating whether the presence of IDC-P can be affected by ADT (androgen deprivation therapy). Methods: We retrospectively evaluated 152 high risk prostate cancer patients who underwent radical prostatectomy with neoadjuvant ADT. They were diagnosed and treated at author-affiliated hospitals between 1991 and 2005. All patient data was made available from slides prepared from prostate needle biopsy samples and prostatectomy specimens and each patient received ADT before operation. Slides were re-reviewed by a single genitourinary pathologist (T.T.) according to the 2005 International Society of Urological Pathology (ISUP) grading system and presence of IDC-P was defined using previously published diagnostic criteria. Results: Patient median age was 68 years (range 46-80 years). The median iPSA was 32.7 ng/ml (range 2.4-296). The median follow-up period was 109 months (range 11-257). Sixty-one patients (40%) were ≥cT3 and 113 cases (74%) had biopsy Gleason score ≥8. Preoperative median ADT period was 4 months (range 1–20 ). IDC-P component was detected in 54 patients (36%) in needle biopsy and 69 (45%) in prostatectomy. There were 28 patients who died of the disease and 12 patients who died of other causes during follow-up. They were divided in 4 groups according to with or without IDC-P in biopsy/prostatectomy (-/- 68cases ,-/+ 30, +/- 15, +/+ 39). Twenty eight per cent of IDC-P positive cases in biopsy showed disappearance of IDC-P in prostatectomy specimen. Prognosis was the worst in +/+ group and IDC-P disappearance cases (+/-) tended to have better survival than IDC-P existing cases (+/+) in CSS (p = 0.04). Conclusions: In a number of IDC-P-positive cases determined by needle biopsy, the disappearance of IDC-P in prostatectomy specimens after ADT indicates the possibility that part of IDC-P positive patients can occasionally respond to ADT.

Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer

2020 ◽  
Author(s):  
Lungwani Muungo
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factor ◽  
Hazard Analysis ◽  
Critical Role ◽  
Immunohistochemical Analysis ◽  
Lncap Cells ◽  
Cancer Specific Survival ◽  
High Gleason Score ◽  
Castrate Resistant ◽  
Transcription Factor 1

The androgen receptor (AR) plays a critical role in the development and the progression of prostate cancer. Alterations in theexpression of AR coregulators lead to AR hypersensitivity, which is one of the mechanisms underlying the progression ofprostate cancer into a castrate-resistant state. Octamer transcription factor 1 (Oct1) is a ubiquitous member of the POUhomeodomainfamily that functions as a coregulator of AR. In our study, the contribution of Oct1 to prostate cancerdevelopment was examined. Immunocytochemistry analysis showed that Oct1 is expressed in the nuclei of LNCaP cells.siRNA-mediated silencing of Oct1 expression inhibited LNCaP cell proliferation. Immunohistochemical analysis of Oct1expression in tumor specimens obtained from 102 patients with prostate cancer showed a positive correlation of Oct1immunoreactivity with a high Gleason score and AR immunoreactivity (p 5 0.0042 and p &lt; 0.0001, respectively). Moreover,patients with high immunoreactivity of Oct1 showed a low cancer-specific survival rate, and those patients with highimmunoreactivities of both Oct1 and AR exhibited poorer cancer-specific prognosis. Multivariate hazard analysis revealed asignificant correlation between high Oct1 immunoreactivity and poor cancer-specific survival (p 5 0.012). These resultsdemonstrate that Oct1 can be a prognostic factor in prostate cancer as a coregulator of AR and may lead to the developmentof a new therapeutic intervention for prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document